Recruiting Ulcerative Colitis Studies in Lebanon
Descemet Endothelial Thickness Comparison Trial I
Descemet Endothelial Thickness Comparison Trial (DETECT) I is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 160 patients in a 2x2 factorial design. The purpose...
Descemet Endothelial Thickness Comparison Trial II
Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DM...
About Ulcerative Colitis Clinical Trials in Lebanon
Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the innermost lining of the colon and rectum. It typically presents with bloody diarrhea, abdominal pain, and urgency. Treatment includes aminosalicylates, corticosteroids, immunosuppressants, and biologics.
There are currently 2 ulcerative colitis clinical trials recruiting participants in Lebanon, NH. These studies are seeking a combined 220 participants. Research is being sponsored by Stanford University. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ulcerative Colitis Clinical Trials in Lebanon — FAQ
Are there ulcerative colitis clinical trials in Lebanon?
Yes, there are 2 ulcerative colitis clinical trials currently recruiting in Lebanon, NH. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lebanon?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lebanon research site will contact you about next steps.
Are clinical trials in Lebanon free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lebanon studies also compensate for your time and travel.
What ulcerative colitis treatments are being tested?
The 2 active trials in Lebanon are testing new therapies including novel drugs, biologics, and treatment approaches for ulcerative colitis.
Data updated March 2, 2026 from ClinicalTrials.gov